Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia in Remission
Open-data reference.
12 US clinical trials · 5 currently recruiting
Active & Recent Trials
Pilot Study of Reduced Venetoclax Exposure
Northwell Health
NCT07163793
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
NCT05794880
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X
NCT06462365
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03670966
Ziftomenib Maintenance Post Allo-HCT
Massachusetts General Hospital
NCT06440135
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Center for International Blood and Marrow Transplant Research
NCT05224661
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
NCT03286530
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
NCT04062266
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
NCT03560752
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Baylor College of Medicine
NCT05236764
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 5 |
| Phase 2 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Acute Myeloid Leukemia in Remission Trial Landscape
ClinicalTrials.gov lists 12 US studies indexed under Acute Myeloid Leukemia in Remission, and 5 of those are currently open to recruitment — roughly 42% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Acute Myeloid Leukemia in Remission shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Acute Myeloid Leukemia in Remission is led by City of Hope Medical Center with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 12 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Acute Myeloid Leukemia in Remission?
PlainTrial tracks 12 US clinical trials for Acute Myeloid Leukemia in Remission, of which 5 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Acute Myeloid Leukemia in Remission?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.